In practicing addiction medicine and psychiatry, I have found that the judicious use of Ambien or Sonata has a place in the management of early abstinence, especially since insomnia is an oft-cited cause of relapse. However, the use of Benadryl and Vistaril are problematic in the treatment of insomnia and anxiety in the substance dependent population.
Read More
While there are plenty of excessively complicated classifications of sleep disorders in this world, TCR, in the midst of a sleep-deprived delirium, has decided that psychiatrists should become most familiar with the following four common problems ...
Read More
While sleeping pills have been around for a long time, the modern age of hypnotics began December 16, 1992, when the FDA approved Ambien (zolpidem). Sonata (zaleplon), a late bloomer, received approval in 1999.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
